|
Video: What is a Stock Split?
|
|
CNS Pharmaceuticals is a clinical pharmaceutical company. Co. focuses on the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. Co.'s primary focus is on the development and testing of Berubicin, a development stage anthracycline intended to treat glioblastoma. Berubicin intercalates into deoxyribonucleic acid (DNA) and interrupts topoisomerase II activity, resulting in the inhibition of DNA replication and repair, and RNA and protein synthesis. According to our CNS Pharmaceuticals stock split history records, CNS Pharmaceuticals has had 1 split. | |
|
CNS Pharmaceuticals (CNSP) has 1 split in our CNS Pharmaceuticals stock split history database. The split for CNSP took place on November 29, 2022. This was a 1 for 30 reverse split, meaning for each 30 shares of CNSP owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 33.3333333333333 share position following the split.
When a company such as CNS Pharmaceuticals conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the CNS Pharmaceuticals stock split history from start to finish, an original position size of 1000 shares would have turned into 33.3333333333333 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into CNS Pharmaceuticals shares, starting with a $10,000 purchase of CNSP, presented on a split-history-adjusted basis factoring in the complete CNS Pharmaceuticals stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
11/11/2019 |
|
End date: |
04/26/2024 |
|
Start price/share: |
$127.50 |
|
End price/share: |
$0.21 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-99.83% |
|
Average Annual Total Return: |
-76.13% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$16.86 |
|
Years: |
4.46 |
|
|
|
Date |
Ratio |
11/29/2022 | 1 for 30 |
|
|